🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A Comparison of Society Guidelines in the Management of Gallbladder Polyps 🔪👁️ herb chen Paula Ferrada MD FACS FCCM MAMSE Julio Mayol Steven D Wexner MD, PhD Dr Luis Felipe Cabrera Vargas MD FACS MACC MACCVA @Cirbosque Andre Campbell, MD, FACS, FACP, FCCM, MAMSE, FCCOS Bellal Joseph Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Sergey Minaev Link: americanjournalofsurgery.com/article/S0002-…

It’s POD 13 and this is the nightmare 😨 of every pancreas surgeon out there… 🩸What’s your strategy to prevent it?! (No need to disclose it’s a bleeding from the GDA stump…)

Today JAMA Surgery: long term outcomes #ESCAPE RCT: early #surgery remains superior to #endoscopy in pts w/ wide-duct #chronic #pancreatitis (morphine-dependent) ✅ Lower Izbicki pain scores ✅ Lower number of reinterventions ✅ Lower VAS pain scores ✅ Higher patient

#AudioVisualAbstract : Revisiting the Malignant Masquerade at the #LiverHilum : Have We Made Progress? Anish Jay Jain MD Mateo Lendoire MD Timothy Newhook rdcu.be/d08fy Syed Nabeel Zafar Syed A. Ahmad

How common is recurrent cholangitis after Whipple/HJ without HJ-stenosis (NSC)? And how to treat? Today in @HPBjournal 🔑 50 of 1179 (4.2%) pts with HJ developed non-stenotic cholangitis NSC. 🔑 'step-up approach' with short-course antibiotics (n = 50, 100 %), prolonged

Reoperation for pancreatic fistula 🐳 🤜🤛 Completion pancreatectomy or pancreas-preserving procedures ?! 💦 Drainage / wirsungostomy most used 44% vs. Completion panc 37% 😱 Mortality as high as 67%! 👀 What is your policy? Thoughts? 🆓 paper 👉 hpbonline.org/article/S1365-…

🎗️ This Pancreatic Cancer Awareness Month, we’re spotlighting research shaping treatment strategies: Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials This meta-analysis examined

#HCC #livertwitter #MedEd 📷 Issue on combined locoregional and systemic treatment for hepatocellular carcinoma 👏The study explores the efficacy of combining locoregional and systemic treatments for HCC. Don't miss this valuable read! 👇 🔗f.oaes.cc/xmlpdf/4ef7613…

Incidence of hepatobiliary malignancies in PSC CGH doi.org/10.1016/j.cgh.… 🔎 systematic review & meta-analysis: 51 studies, 26482 pts 👉High incidence of CCA, HCC & GBC are rare 👉PSC-IBD pts may be at higher risk for HCC ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Distal pancreatectomy 🧐 to drain or not to drain !? 🪡 1.2k resections at Mass General Surgery 🛁 Fluid colletions in 1/2 who received CT scan but 70% asymptomatic ❌ and 25% POPF 🐳 Surgical drains led to higher rates of POPF The dilemma continues... 🤯 journals.lww.com/annalsofsurger…

Last but not least: state data analysis by Pei-Wen Lim MD MS-HPEd FACS | 林佩雯 Zhi Ven Fong, MD MPH DrPH of 5446 patients undergoing bailout for severe cholecystitis showed conversion to open had the highest bile duct injury rate (4.4%) vs subtotal cholecystectomy (0.5%) or cholecystostomy tube (0.2%) #AmerSurg25

Biliopathy in EHPVO often tied to PVT in mesenteric veins or acute bile duct angle (110° vs 128°). Ranges from asymptomatic to choledocholithiasis, cholangitis, or cirrhosis. Natural history unclear; manage with ERCP/stenting for symptoms. #Radiology #Hepatology

Postop ⬆️ amylasemia and acute pancreatitis 🧪 systematic review and meta analysis 🐳 POH predicts POPF ⚡️ PPAP causes POPF, DGE, PPH and mortality 👉 Check amylase early and get ready to mitigate 🧯postop complications! sciencedirect.com/science/articl…

Dr. Dr. Nina Niu Sanford discusses the PANOVA-3 trial, which found an improvement in OS for pts w unresectable, locally adv pancreatic adenocarcinoma treated in the first line w TTFields concomitant w gemcitabine & nab-paclitaxel. Learn more: brnw.ch/21wT4bx #ASCO25

Pre-operative mFOLFIRINOX or PAXG regimen for stage I-III #PDAC #ASCO25 🔎Phs-III 👉mEFS 16.2 vs 10 mo 👉mOS 37 vs 26 mo 🧐 OS benefit, but intensive treatment ESMO - Eur. Oncology

Tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for LA-PDAC #ASCO25 🔎PANOVA-3 phs 3 👉mPFS 10.6 vs9.3 mo 👉mDFS 13.9 vs 11.5 👉mOS 16.2 vs 14.2 mo 👉better Qol & pain free survival, but skin tox 🧐Positive, but interesting to see whether & how it will

📗Management of HCC CA: A Cancer Journal for Clinicians ✅ A review from diagnosis to treatments 👉doi.org/10.3322/caac.7… OncoAlert #cancer #Oncology #MedX #liver

June Issue: Long-Term Outcomes According to #SurgicalMargin in Mass-Forming #Cholangiocarcinoma : The Role of R1vasc Flavio Milana GUIDO TORZILLI Simone Famularo rdcu.be/eqpcG Vitor Moutinho, MD, MSc Syed A. Ahmad